#acceleron pharma

Medicine’s Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations

Contact it the Industrial Revolution for healthcare, the century of biology, Moore’s Legislation for medication, or all 3. Whichever metaphor you select, the which means is the identical: Many thanks to our quickly evolving knowledge of biology and the application of new technological tools—and a little bit of urgency sparked by the Covid pandemic—explosive adjust is coming in our capacity to…

Mirati Therapeutics (MRTX:NAS) Fundamental Valuation Report

Fundamental Valuation Report Mirati Therapeutics(MRTX:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$144.00 (USD) 05/07/2021 Weighted Valuation$148.78 (USD) Overall RatingFairly valued to slightly Undervalued by 3.3% Valuation Models Comparables: $165.51 (USD) Adjusted Book…

Mirati Therapeutics (MRTX:NAS) Fundamental Valuation Report

Fundamental Valuation Report Mirati Therapeutics(MRTX:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$144.00 (USD) 05/07/2021 Weighted Valuation$148.78 (USD) Overall RatingFairly valued to slightly Undervalued by 3.3% Valuation Models Comparables: $165.51 (USD) Adjusted Book…

BridgeBio Pharma (BBIO:NAS) Fundamental Valuation Report

Fundamental Valuation Report BridgeBio Pharma(BBIO:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$55.12 (USD) 04/16/2021 Weighted Valuation$37.29 (USD) Overall RatingOvervalued by 32.3% Valuation Models Comparables: $37.29 (USD) Valuation Methods This company is: Cash…

Moderna (MRNA:NAS) Fundamental Valuation Report

Fundamental Valuation Report Moderna(MRNA:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$133.28 (USD) 03/26/2021 Weighted Valuation$180.43 (USD) Overall RatingUndervalued by 35.4% Valuation Models Comparables: $193.12 (USD) Valuation Methods This company is: Cash…

Top Pharma News of the Week – July 9th

All The Most Important Pharmaceutical News Stories Of The Week – July 2018 – Week #2 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

July 2, 2018

Merck, known as MSD outside the United States and Canada, has announced that the…

Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza

Lebanon, NH – January 9, 2015 – Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology, Inc. and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize…